Jagsonpal Pharmaceuticals Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2025
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals held its 46th AGM on September 24, 2025, via video conferencing, and all six resolutions were passed with overwhelming shareholder approval. Out of 25,344 shareholders on record date (Sept 17, 2025), about 77.3% of total shares (5.15 crore out of 6.66 crore) were voted. The key resolutions included adoption of audited financial statements for FY25, declaration of dividend for FY25, reappointment of Mr. Manish Gupta (DIN:06805265) as director, ratification of cost auditors' remuneration, revision in MD Manish Gupta's remuneration (passed as a special resolution with 99.81% in favour), and appointment of the secretarial auditor. Promoters holding 4.5 crore shares voted 100% in favour of every resolution. Mr. Gupta's own 17.11 lakh shares were excluded from voting on resolutions where he was deemed interested.
Strong shareholder approval across all six resolutions signals smooth governance and broad consensus. The declaration of dividend and hike in MD remuneration are shareholder-endorsed, with no significant dissent. No material controversy or negative signal for the stock.